First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Heron Therapeutics: the story is balanced — ZYNRELEF quarterly prescription volume trends and hospital formulary adoption rates across soft tissue and orthopedic…
★ Analysts see FY2026 revenue reaching $168M — +8.5% growth in a single year.
What Moves the Stock
1ZYNRELEF quarterly prescription volume trends and hospital formulary adoption rates across soft tissue and orthopedic procedures
2Commercial execution updates including sales force productivity, market penetration in ambulatory surgical centers versus hospital outpatient departments
3Clinical data releases or label expansion opportunities for ZYNRELEF in additional surgical procedures (orthopedic, spine)
4Cash runway visibility and financing needs given negative operating cash flow and high debt/equity ratio of 9.44x
5Competitive dynamics in post-surgical pain management including generic competition and alternative non-opioid therapies
6ZYNRELEF (post-surgical pain management) - estimated 60-70% of revenue, launched 2021 for soft tissue procedures
speculative growth - The stock attracts high-risk tolerance investors seeking asymmetric upside from successful commercial execution…
Rising interest rates create multiple headwinds: (1) increased debt service costs on the company's substantial debt load (9.44x debt/equity)…
Watch on earnings: ZYNRELEF quarterly net revenue and prescription volume growth rates, Operating cash flow burn rate and months of cash runway remaining, Total debt outstanding and weighted average interest rate on debt facilities.
One Sentence Summary:
Heron Therapeutics: the story is balanced — zynrelef quarterly prescription volume trends and hospital formulary adoption rates across soft tissue and orthopedic procedures.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.